261 related articles for article (PubMed ID: 24442756)
1. Potential role of N-acetylcysteine in the management of substance use disorders.
McClure EA; Gipson CD; Malcolm RJ; Kalivas PW; Gray KM
CNS Drugs; 2014 Feb; 28(2):95-106. PubMed ID: 24442756
[TBL] [Abstract][Full Text] [Related]
2. The Role of Pharmacotherapy in the Treatment of Adolescent Substance Use Disorders.
Hammond CJ
Child Adolesc Psychiatr Clin N Am; 2016 Oct; 25(4):685-711. PubMed ID: 27613346
[TBL] [Abstract][Full Text] [Related]
3. Effects of Beta Lactams on Behavioral Outcomes of Substance Use Disorders: A Meta-Analysis of Preclinical Studies.
Alasmari MS; Almohammed OA; Hammad AM; Altulayhi KA; Alkadi BK; Alasmari AF; Alqahtani F; Sari Y; Alasmari F
Neuroscience; 2024 Jan; 537():58-83. PubMed ID: 38036059
[TBL] [Abstract][Full Text] [Related]
4. N-acetylcysteine as a treatment for substance use cravings: A meta-analysis.
Winterlind EL; Malone SG; Setzer MR; Murphy MA; Saunders D; Gray JC
medRxiv; 2024 May; ():. PubMed ID: 38798604
[TBL] [Abstract][Full Text] [Related]
5. Substance use disorders in military veterans: prevalence and treatment challenges.
Teeters JB; Lancaster CL; Brown DG; Back SE
Subst Abuse Rehabil; 2017; 8():69-77. PubMed ID: 28919834
[TBL] [Abstract][Full Text] [Related]
6. Promising immunomodulators for management of substance and alcohol use disorders.
Acuña AM; Park C; Leyrer-Jackson JM; Olive MF
Expert Opin Pharmacother; 2024 May; 25(7):867-884. PubMed ID: 38803314
[TBL] [Abstract][Full Text] [Related]
7. Neuroimmune Mechanisms as Novel Treatment Targets for Substance Use Disorders and Associated Comorbidities.
Namba MD; Leyrer-Jackson JM; Nagy EK; Olive MF; Neisewander JL
Front Neurosci; 2021; 15():650785. PubMed ID: 33935636
[TBL] [Abstract][Full Text] [Related]
8. Role of antioxidants in the neurobiology of drug addiction: An update.
Kamiński P; Lorek M; Baszyński J; Tadrowski T; Gorzelańczyk EJ; Feit J; Tkaczenko H; Owoc J; Woźniak A; Kurhaluk N
Biomed Pharmacother; 2024 Jun; 175():116604. PubMed ID: 38692055
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic options and challenges for substances of abuse.
Gardner TJ; Kosten TR
Dialogues Clin Neurosci; 2007; 9(4):431-45. PubMed ID: 18286802
[TBL] [Abstract][Full Text] [Related]
10. Targeting the cytoskeleton as a therapeutic approach to substance use disorders.
Pandey S; Miller CA
Pharmacol Res; 2024 Apr; 202():107143. PubMed ID: 38499081
[TBL] [Abstract][Full Text] [Related]
11. Neuromarkers in addiction: definitions, development strategies, and recent advances.
Harp NR; Wager TD; Kober H
J Neural Transm (Vienna); 2024 May; 131(5):509-523. PubMed ID: 38630190
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for the development of new medications for cocaine dependence.
Bough KJ; Amur S; Lao G; Hemby SE; Tannu NS; Kampman KM; Schmitz JM; Martinez D; Merchant KM; Green C; Sharma J; Dougherty AH; Moeller FG
Neuropsychopharmacology; 2014 Jan; 39(1):202-19. PubMed ID: 23979119
[TBL] [Abstract][Full Text] [Related]
13. IUPHAR Review: New strategies for medications to treat substance use disorders.
Montoya ID; Volkow ND
Pharmacol Res; 2024 Feb; 200():107078. PubMed ID: 38246477
[TBL] [Abstract][Full Text] [Related]
14. Neuroimmune modulators as novel pharmacotherapies for substance use disorders.
Grodin EN
Brain Behav Immun Health; 2024 Mar; 36():100744. PubMed ID: 38435721
[TBL] [Abstract][Full Text] [Related]
15. Systematic review of N-acetylcysteine in the treatment of addictions.
Asevedo E; Mendes AC; Berk M; Brietzke E
Braz J Psychiatry; 2014; 36(2):168-75. PubMed ID: 24676047
[TBL] [Abstract][Full Text] [Related]
16. Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review.
Deepmala ; Slattery J; Kumar N; Delhey L; Berk M; Dean O; Spielholz C; Frye R
Neurosci Biobehav Rev; 2015 Aug; 55():294-321. PubMed ID: 25957927
[TBL] [Abstract][Full Text] [Related]
17. Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network.
McClure EA; Sonne SC; Winhusen T; Carroll KM; Ghitza UE; McRae-Clark AL; Matthews AG; Sharma G; Van Veldhuisen P; Vandrey RG; Levin FR; Weiss RD; Lindblad R; Allen C; Mooney LJ; Haynes L; Brigham GS; Sparenborg S; Hasson AL; Gray KM
Contemp Clin Trials; 2014 Nov; 39(2):211-23. PubMed ID: 25179587
[TBL] [Abstract][Full Text] [Related]
18. N-acetylcysteine in the treatment of craving in substance use disorders: Systematic review and meta-analysis.
Duailibi MS; Cordeiro Q; Brietzke E; Ribeiro M; LaRowe S; Berk M; Trevizol AP
Am J Addict; 2017 Oct; 26(7):660-666. PubMed ID: 28898494
[TBL] [Abstract][Full Text] [Related]
19. N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects.
Minarini A; Ferrari S; Galletti M; Giambalvo N; Perrone D; Rioli G; Galeazzi GM
Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):279-292. PubMed ID: 27766914
[TBL] [Abstract][Full Text] [Related]
20. An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers.
McClure EA; Baker NL; Gipson CD; Carpenter MJ; Roper AP; Froeliger BE; Kalivas PW; Gray KM
Am J Drug Alcohol Abuse; 2015 Jan; 41(1):52-6. PubMed ID: 25062287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
